BIOTECH Merger in Action
April 24 Interview with CEO Michael Redman On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company. Verified Company Profile 4/10/2017
AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder
AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc.
Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO
Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.
AEPP Security Details
| ||Market Value1 ||$3,571,704 ||a/o Apr 07, 2017 |
| ||Authorized Shares ||500,000,000 ||a/o Mar 30, 2017 |
| ||Outstanding Shares ||93,911,633 ||a/o Apr 04, 2017 |
| ||-Restricted ||Not Available |
| ||-Unrestricted ||Not Available |
| ||Held at DTC ||Not Available |
| ||Float ||33,311,633 ||a/o Apr 06, 2017 |
| ||Par Value ||Not Available |
Transfer Agent(s) Verified by Transfer Agent
|Shareholders of Record ||101 ||a/o Apr 06, 2017 |
Zero outstanding debt
"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 ”and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).
Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.
Who is Oncolix, Inc.?
April 2017 Company Presentation:
POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN
Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer. This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.
The FDA has also approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity.
Prolanta is currently in FDA clinical trials phase 1.
Oncolix received Orphan Drug Status for their developmental drug Prolanta.
8 U.S. Patents have been awarded in the development of Prolanta
The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.
|Patent Number ||Issue Date ||Issued To ||Title |
|US 7,115,556 ||03 OCT 2006 ||Oncolix ||Use of Anti-Prolactin Agents to Treat Proliferative Conditions |
|US 7,201,905 ||10 APR 2007 ||Oncolix ||Bi-Functional Cancer Treatment Agents |
|US 7,339,027 |
|4 MAR 2008 |
6 NOV 2012
|Oncolix ||Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins |
|US 7,632,809 ||15 DEC 2009 ||Oncolix ||Multimeric Ligands with Enhanced Stability |
|US 8,648,046 |
|11 FEB 2014 |
17 JUN 2014
|Oncolix ||Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells |
|US 8,754,031 ||17 JUN 2014 ||Oncolix ||Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway |
Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer. Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.
The Oncolix Team